Patient characteristics
| Patients . | N (%) . |
|---|---|
| Total | 58 |
| Median age (range), y | 61 (21-85) |
| Sex | |
| Male | 33 (57) |
| Female | 25 (43) |
| Cytogenetic risk | |
| Favorable | 7 |
| Intermediate | 31 |
| Unfavorable | 17 |
| Unknown | 3 |
| CDA status | |
| PM (≤2 U/mg) | 28 (48) |
| EM (2-7 U/mg) | 23 (40) |
| UM (>7 U/mg) | 7 (12) |
| ECOG PS | |
| BM blasts, % | 54 |
| WBC, × 109/L | 22 ± 44 |
| FAB subtype | |
| M0 | 7 |
| M1 | 15 |
| M2 | 14 |
| M4 | 11 |
| M5 | 9 |
| M6 | 1 |
| M7 | — |
| Unclassified AML | 1 |
| Patients . | N (%) . |
|---|---|
| Total | 58 |
| Median age (range), y | 61 (21-85) |
| Sex | |
| Male | 33 (57) |
| Female | 25 (43) |
| Cytogenetic risk | |
| Favorable | 7 |
| Intermediate | 31 |
| Unfavorable | 17 |
| Unknown | 3 |
| CDA status | |
| PM (≤2 U/mg) | 28 (48) |
| EM (2-7 U/mg) | 23 (40) |
| UM (>7 U/mg) | 7 (12) |
| ECOG PS | |
| BM blasts, % | 54 |
| WBC, × 109/L | 22 ± 44 |
| FAB subtype | |
| M0 | 7 |
| M1 | 15 |
| M2 | 14 |
| M4 | 11 |
| M5 | 9 |
| M6 | 1 |
| M7 | — |
| Unclassified AML | 1 |
ECOG PS, Eastern Cooperative Oncology Group performance status; FAB, French American British; WBC, white blood cell count.